BeiGene (BGNE) News Today $183.24 -0.91 (-0.49%) (As of 12:45 PM ET) Add Compare Share Share Today's Range$180.32▼$184.3550-Day Range$158.67▼$201.5852-Week Range$156.56▼$280.62Volume94,324 shsAverage Volume221,715 shsMarket Capitalization$17.45 billionP/E RatioN/ADividend YieldN/APrice Target$278.08 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBellevue Group AG Has $1.82 Million Stock Holdings in BeiGene, Ltd. (NASDAQ:BGNE)marketbeat.com - December 6 at 10:17 AMBeiGene Stock (NASDAQ:BGNE) Earnings Dates and Earning Callsbenzinga.com - December 3 at 8:36 AMBeiGene Stock (NASDAQ:BGNE) Dividends: History, Yield and Datesbenzinga.com - December 3 at 8:36 AMBeiGene, Ltd. (NASDAQ:BGNE) Short Interest Up 23.3% in Novemberamericanbankingnews.com - December 3 at 3:36 AMWall Street Analysts Think BeiGene, Ltd. (BGNE) Could Surge 44.28%: Read This Before Placing a Betfinance.yahoo.com - November 30 at 2:16 PMBeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023finance.yahoo.com - November 29 at 6:43 PMBeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023finance.yahoo.com - November 28 at 9:59 AMAnalysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Karuna Therapeutics (KRTX) and Theseus Pharmaceuticals (THRX)markets.businessinsider.com - November 23 at 7:45 PMThe Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeuticsfinance.yahoo.com - November 21 at 12:35 PMBeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitorfinance.yahoo.com - November 21 at 7:35 AMBeiGene's Brukinsa gets Europe approval for follicular lymphomamsn.com - November 17 at 10:35 AMBeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphomafinance.yahoo.com - November 17 at 10:35 AMBAKER BROS. ADVISORS LP Bolsters Position in BeiGene Ltdfinance.yahoo.com - November 15 at 7:19 AMBuy Recommendation for BeiGene: Strong Sales, Potential FDA Approval, and Improved Operating Efficienciesmarkets.businessinsider.com - November 14 at 10:49 PMWall Street Analysts Believe BeiGene, Ltd. (BGNE) Could Rally 32.87%: Here's is How to Tradefinance.yahoo.com - November 14 at 12:48 PMDecoding BeiGene Ltd (BGNE): A Strategic SWOT Insightfinance.yahoo.com - November 10 at 10:17 AMBeiGene ADS: EPS übertrifft Schätzungen um 5,40 $ - Umsatz besser als erwartetde.investing.com - November 9 at 11:44 PMBeiGene, Ltd.: BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updatesfinanznachrichten.de - November 9 at 6:43 PMBeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updatesfinance.yahoo.com - November 9 at 6:43 PMBeiGene, Ltd.: BeiGene to Present at the Jefferies London Healthcare Conferencefinanznachrichten.de - November 8 at 10:06 AMBeiGene to Present at the Jefferies London Healthcare Conferencefinance.yahoo.com - November 8 at 10:06 AMBeiGene, Ltd.'s (NASDAQ:BGNE) one-year returns climbed after last week's 8.9% gain, institutional investors must be happyfinance.yahoo.com - November 2 at 3:44 PMBeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in ...businesswire.com - October 27 at 12:28 PMBRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemiafinance.yahoo.com - October 20 at 10:42 AMBeiGene: Staying On The Sidelines (Rating Downgrade)msn.com - October 19 at 11:54 AMBeiGene's Poster For Upcoming Conference Reveals Promising Lung Cancer Datamsn.com - October 18 at 3:44 PMBeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)finance.yahoo.com - October 17 at 5:32 PMBeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinomafinance.yahoo.com - October 17 at 5:32 PMBeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assetsfinance.yahoo.com - October 16 at 10:26 AMNational Bank of Canada FI Increases Holdings in BeiGene, Ltd. (NASDAQ:BGNE)marketbeat.com - October 15 at 5:23 AMBeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphomafinance.yahoo.com - October 13 at 4:01 PMBaillie Gifford & Co. Sells 34,058 Shares of BeiGene, Ltd. (NASDAQ:BGNE)marketbeat.com - October 12 at 3:16 PMBeiGene (NASDAQ:BGNE investor three-year losses grow to 43% as the stock sheds US$1.4b this past weekfinance.yahoo.com - October 6 at 7:04 PMStockNews.com Upgrades BeiGene (NASDAQ:BGNE) to "Hold"marketbeat.com - October 3 at 3:30 AMFirst Trust Direct Indexing L.P. Has $637,000 Holdings in BeiGene, Ltd. (NASDAQ:BGNE)marketbeat.com - September 24 at 5:23 AMLeerink Partnrs Brokers Decrease Earnings Estimates for BeiGene, Ltd. (NASDAQ:BGNE)marketbeat.com - September 22 at 7:13 AMCitigroup Maintains Buy Rating for BeiGene: Here's What You Need To Knowmarkets.businessinsider.com - September 21 at 1:52 PMBeiGene (NASDAQ:BGNE) Price Target Raised to $290.00marketbeat.com - September 21 at 7:38 AMBeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA ® (tislelizumab)businesswire.com - September 19 at 2:20 PMBeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRAbusinesswire.com - September 19 at 2:20 PMBeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)uk.finance.yahoo.com - September 19 at 9:20 AMBeiGene, Ltd.: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA (tislelizumab)finanznachrichten.de - September 19 at 9:20 AMBeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®finance.yahoo.com - September 19 at 9:20 AMBeiGene, Ltd. (NASDAQ:BGNE) Holdings Trimmed by SG Americas Securities LLCmarketbeat.com - September 18 at 6:30 AMThe Latest Analyst Ratings for BeiGenebenzinga.com - September 12 at 6:37 PMProShare Advisors LLC Sells 1,002 Shares of BeiGene, Ltd. (NASDAQ:BGNE)marketbeat.com - September 8 at 4:37 AMCelgene Enters PD1 Market with BeiGene Dealthestreet.com - September 1 at 11:23 PMBeiGene to Present at the Morgan Stanley 21 st Annual Global Healthcare Conferencebusinesswire.com - September 1 at 3:59 AMRussell Investments Group Ltd. Boosts Stake in BeiGene, Ltd. (NASDAQ:BGNE)marketbeat.com - August 22 at 4:46 AMConnor Clark & Lunn Investment Management Ltd. Reduces Position in BeiGene, Ltd. (NASDAQ:BGNE)marketbeat.com - August 18 at 6:46 AM Get BeiGene News Delivered to You Automatically Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address BGNE Media Mentions By Week BGNE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BGNE News Sentiment▼0.640.43▲Average Medical News Sentiment BGNE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BGNE Articles This Week▼54▲BGNE Articles Average Week Get BeiGene News Delivered to You Automatically Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BMRN News Today GMAB News Today ALNY News Today RDY News Today TEVA News Today VTRS News Today LEGN News Today UTHR News Today VRNA News Today SRPT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:BGNE) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeiGene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.